EDGEMOND JAMES sold $912K of UTHR
EDGEMOND JAMES (CFO AND TREASURER) sold 1,605 shares of UNITED THERAPEUTICS Corp (UTHR) at $567.91 ($0.91M total) on 2026-05-28 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Because the plan is pre-arranged, the disclosure is more about compliance/position management than a fresh fundamental catalyst.
Market read
Traders may note the insider sale for sentiment, but it is unlikely to drive a standalone repricing absent other catalysts.
What to watch
The dollar amount is modest relative to typical institutional flows; without buy/sell netting across insiders, signal quality is limited.
Background
This is an SEC Form 4 insider transaction: an officer (CFO/treasurer) reports an open-market sale under a pre-arranged Rule 10b5-1 plan.
Ticker impact
United Therapeutics CFO and treasurer Edgemond James sold 1,605 shares in an open-market transaction disclosed on SEC Form 4.
Likely minimal price impact; any effect would be short-lived unless followed by additional insider activity or fundamental news.
The filing specifies a Rule 10b5-1 pre-arranged plan, which reduces the likelihood the sale reflects new, nonpublic information.
Market effects
No clear sector read-through from a single 10b5-1 insider sale at one issuer.
None.
None.
Counterpoint
Even with 10b5-1, repeated insider selling can coincide with periods of valuation or risk management rather than information—watch for clustering across officers.
Key entities
- issuerUnited Therapeutics Corp
Subject of the insider transaction disclosure (Form 4).
- insiderEdgemond James
CFO and treasurer who sold shares under a 10b5-1 plan.
